Innovation Theater 7 | Provided by: Sanofi

---

Program Description:

Join us for a focused scientific session highlighting the latest evidence informing how Alpha‑1 Antitrypsin Deficiency (AATD) is detected, characterized, and targeted therapeutically. This session will synthesize emerging insights in AAT restoration and evolving clinical endpoints that are shaping the next generation of AATD research and clinical practice.

Key Topics Covered:

Underscore the importance of alpha-1 antitrypsin deficiency (AATD) screening and urgent need for new therapeutic options.

Elucidate the evidence supporting the need to restore AAT levels to the normal range.

Highlight recent and ongoing innovations in clinical trial design for AATD that are driving more precise and patient‑focused research.

Why this session matters:

AATD science is rapidly advancing with important implications for diagnosis, treatment goals, and trial design. Don’t miss this session to stay aligned with the evolving evidence driving the future of AATD care and investigation.